Summary
Majority of claims are not supported by the provided label; only a minority align (indication and dosing). Numerous non-labeled adverse-event frequencies and comparisons are asserted, and several statements are not reflected in the labeling.
Category Scores
Accurate Statements
Topamax (topiramate) is an anticonvulsant used for epilepsy and migraine prevention.
Indication for epilepsy and migraine prophylaxis; label sections 1, 2.3.
Topiramate blocks voltage-gated sodium channels.
12.1 Mechanism of Action (topiramate inhibits sodium channels).
Topiramate enhances GABA activity.
12.1 Mechanism of Action (GABAergic effects).
Encephalopathy can occur.
6.2 Postmarketing Experience mentions encephalopathy.
Starting dose is 25 mg/day.
2.3 Preventive Treatment of Migraine dosing table shows Week 1: 25 mg (evening).
Titration should be slow over weeks to minimize neurological issues.
2.3 Dosing/titration guidance for migraine prophylaxis.
Topiramate inhibits carbonic anhydrase (acetazolamide-like inhibition).
12.1 Carbonic anhydrase inhibition noted.
Unsupported Statements
Topiramate commonly causes paresthesia up to 51%.
Label does not provide a 51% frequency for paresthesias.
Topiramate commonly causes dizziness up to 28%.
No labeled frequency for dizziness provided in the excerpt.
Topiramate commonly causes somnolence up to 30%.
No labeled frequency for somnolence provided in the excerpt.
Topiramate commonly causes headache up to 26%.
No labeled frequency for headache provided in the excerpt.
The incidence of neurological side effects is higher with epilepsy doses over 200 mg/day than with migraine prophylaxis at 100 mg/day.
Label does not provide a dose-based comparative incidence.
Children report cognitive effects like confusion up to 14%.
Pediatric cognitive-frequency data not described in the labeled sections provided.
Elderly patients report cognitive effects like psychomotor slowing up to 11%.
Elderly cognitive-frequency data not described in the labeled sections provided.
In clinical trials, 15-20% of users discontinued due to nervous system adverse events.
Discontinuation rates for CNS AEs not provided in label excerpt.
Cognitive impairment ('Dopamax') occurs in 6-10%.
No labeled frequency for 'Dopamax' cognitive impairment.
Psychosis is rare (<1%).
No labeled frequency for psychosis provided in the excerpt.
Acute myopia occurs in 0.1-2%.
Frequency not specified in label excerpt; acute myopia/angle-closure described without percentage.
Glaucoma occurs in 0.1-2%.
Frequency not specified in label excerpt; secondary angle-closure glaucoma described without percentage.
Status epilepticus has occurred during abrupt withdrawal.
Abrupt withdrawal risks discussed generally; not explicit as a label frequency in excerpt.
Sudden discontinuation heightens seizure risk in epileptics.
Not explicitly stated in the provided label excerpt.
Sudden discontinuation heightens rebound migraines.
Not explicitly stated in the provided label excerpt.
Anxiety may worsen temporarily after rapid reversal of brain adaptation.
Not explicitly stated in the provided label excerpt.
Insomnia may worsen temporarily after rapid reversal of brain adaptation.
Not explicitly stated in the provided label excerpt.
Compared with propranolol for migraines, Topamax has more cognitive side effects.
No labeled comparative cognitive side-effect data in provided sections.
Compared with valproate for migraines, Topamax has more cognitive side effects.
No labeled comparative cognitive data in provided sections.
Compared with propranolol for migraines, Topamax has fewer weight gain issues.
No labeled comparative weight data in provided sections.
Compared with valproate for migraines, Topamax has fewer weight gain issues.
No labeled comparative weight data in provided sections.
Compared with levetiracetam for seizures, Topamax causes more paresthesia.
No labeled comparative paresthesia data in provided sections.
Compared with levetiracetam for seizures, Topamax causes less behavioral agitation.
No labeled comparative behavioral data in provided sections.
Hydration helps paresthesia.
Not described in the label.
Cognitive effects often improve with time.
Not described in the label.
Cognitive effects often improve with dose reduction.
Not described in the label.
Monitoring electrolytes is key due to carbonic anhydrase inhibition.
No label directive mandating electrolyte monitoring in the provided excerpt.
Contradictions
Important Omissions
Critical warnings and precautions from the label (e.g., suicidal behavior/ideation 5.5; metabolic acidosis 5.4; oligohidrosis and hyperthermia 5.3; acute myopia/angle-closure glaucoma 5.1; postmarketing 6.2) are not reflected in the claims.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Inclusion of non-label adverse-event frequencies and unsupported comparisons increases risk of misinforming safety.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Non-label claims and unsupported adverse-event data; insufficient coverage of critical safety content.
Suggested Improvement
Limit statements to those supported by the prescribing information; provide labeled adverse events with frequencies; include boxed warnings and major precautions (5.1, 5.3, 5.4, 5.5, 5.6, 6.2); avoid drug-disease or drug-comparator comparisons not in label; verify dosing statements against Table 3.